Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotech company developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Dr. Taylor Schreiber, Shattuck's CEO, will engage in a fireside chat with BTIG analyst Kaveri Pohlman on August 5 at 2:00 p.m. ET. The company will also be available for one-on-one meetings during the conference. A live webcast of the fireside chat will be accessible to conference participants.
Positive
- None.
Negative
- None.
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-one meetings at BTIG’s Virtual Biotechnology Conference, taking place August 5-6, 2024.
Presentation Details
Conference: BTIG Virtual Biotechnology Conference
Format: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: August 5, 2024
Time: 2:00 p.m. ET
A live webcast of the fireside chat will be available to conference participants. If you are interested in meeting with the Shattuck team during the conference, please reach out to your BTIG representative.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary ARC® platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) participating in the BTIG Virtual Biotechnology Conference?
Who will represent Shattuck Labs (STTK) at the BTIG Virtual Biotechnology Conference?
What type of products is Shattuck Labs (STTK) developing?
Will there be a webcast of Shattuck Labs' (STTK) presentation at the BTIG conference?
